Barclays Raises Johnson & Johnson (JNJ) Price Target After Updated Estimates

Core Insights - Johnson & Johnson (NYSE: JNJ) is recognized among the 15 Dividend Stocks that outperform the S&P 500 [1] - Barclays has raised its price target for JNJ to $197 from $176 while maintaining an Equal Weight rating [2] - The company has a strong balance sheet that supports consistent stability and allows for significant investments in R&D and acquisitions, including the recent $3.05 billion purchase of Halda Therapeutics to enhance its oncology pipeline [3] - JNJ focuses on high-margin, innovation-driven categories within its Innovative Medicine unit, including oncology, immunology, and neuroscience, while its MedTech segment targets faster-growing markets like surgical robotics and digital surgery [4] - For Q3, JNJ reported net sales of $24 billion, a 6.8% year-over-year increase, and a net income surge of 91% to $5.2 billion [4] Company Overview - Johnson & Johnson operates globally across two core segments: Innovative Medicine and MedTech [5]